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A B S T R A C T
A growing body of evidence suggests a role of proteolytic enzymes in the development of diabetic nephropathy.
Cathepsin C (CatC) is a well-known regulator of inflammatory responses, but its involvement in podocyte and
renal injury remains obscure. We used Zucker rats, a genetic model of metabolic syndrome and insulin re-
sistance, to determine the presence, quantity, and activity of CatC in the urine. In addition to the animal study,
we used two cellular models, immortalized human podocytes and primary rat podocytes, to determine mRNA
and protein expression levels via RT-PCR, Western blot, and confocal microscopy, and to evaluate CatC activity.
The role of CatC was analyzed in CatC-depleted podocytes using siRNA and glycolytic flux parameters were
obtained from extracellular acidification rate (ECAR) measurements. In functional analyses, podocyte and glo-
merular permeability to albumin was determined. We found that podocytes express and secrete CatC, and a
hyperglycemic environment increases CatC levels and activity. Both high glucose and non-specific activator of
CatC phorbol 12-myristate 13-acetate (PMA) diminished nephrin, cofilin, and GLUT4 levels and induced cy-
toskeletal rearrangements, increasing albumin permeability in podocytes. These negative effects were com-
pletely reversed in CatC-depleted podocytes. Moreover, PMA, but not high glucose, increased glycolytic flux in
podocytes. Finally, we demonstrated that CatC expression and activity are increased in the urine of diabetic
Zucker rats. We propose a novel mechanism of podocyte injury in diabetes, providing deeper insight into the role
of CatC in podocyte biology.
1. Introduction
Increased activity of proteolytic enzymes has been suggested to
promote injury to the renal filtration barrier and renal function [1]. The
mechanisms underlying protease-mediated damage comprise the de-
regulated proteolysis of glomerular basement membrane (GBM) com-
ponents, proteolysis of non-GBM proteins, and alteration of glomerular
metabolism [1]. Immune cells are thought to be the main source of
active proteases, but recent findings have highlighted the role of renal
cells in the production of a wide range of proteases in response to
different stimuli. Proteases play an important role in the physiology and
function of podocytes, and some of them (cathepsin L, D, calpain,
caspase 1, metalloproteases 2 and 9, dipeptidyl peptidase 4 [DPP-4])
are well-described in the literature [2–6].
For example, activation of cathepsin L-mediated proteolysis has
been suggested as one of the major causes of foot process effacement
and proteinuria [7]. Moreover, DPP-4 has been shown to be expressed
in podocytes in patients with diabetic nephropathy, but not in healthy
individuals [8]. In addition to a range of proteolytic enzymes, podo-
cytes also express protease-activated receptors (PARs) 1–4, and the
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T
roles of PAR1, PAR2, and PAR3 have been studied in podocytes thus far
[9–11]. However, to the best of our knowledge, no research on cathe-
psin C (CatC) in podocytes has been published.
CatC (EC 3.4.14.1), also known as dipeptidyl peptidase 1, is a tet-
rameric cysteine protease with a molecular weight of ~200 kDa
[12,13]. It is expressed ubiquitously, with the most prominent expres-
sion in the lungs, placenta, spleen, and kidneys [14]. CatC is synthe-
sized as a proteolytically inactive zymogen (~52 kDa), and then pro-
cessed in a series of proteolytic cleavages to produce a mature form of
the enzyme, which is composed of three subunits: N-terminal exclusion
domain chain with three glycosylation sites (~16 kDa), a catalytic
heavy chain with one glycosylation site (~23 kDa), and a light chain
(~7.5 kDa) [12,13]. The functional tetramer is made of four identical
heterotrimers. At a slightly acidic pH (4.5–6.8), CatC exhibits broad
substrate activity, and its catalytic action involves the removal of di-
peptides from the N-terminus of the substrate [15]. The most char-
acterized CatC substrates belong to the granule-associated serine pro-
teases: cathepsin G, proteinase 3, human neutrophil elastase, mast cell
chymase, and granzymes A and B [16]. The upstream CatC activators
include cathepsins L, S, V, and K, which are proposed to play a role in
its proteolytic maturation [17,18].
Alterations in the concentration and activity of different proteases in
urine have been reported in diabetic patients and experimental animal
models, some of which are proposed to serve as biomarkers of renal
complications in diabetes, including cathepsin B and D, kallikrein 4,
and DPP-4 [19–21]. Moreover, non-obese diabetic (NOD) mice have
been reported to be partially protected from the development of dia-
betes when lacking cathepsin S (Ctss ̶̶ / ̶)̶ or cathepsin B (Ctsb ̶̶ / ̶)̶,
whereas cathepsin L knockouts (Ctsl ̶̶ / ̶̶) are fully resistant to diabetes
[22]. Elevated expression and urinary activity of DPP-4 has been linked
to renal fibrosis in diabetic nephropathy, and DPP-4 inhibitors are used
as potent hypoglycemic drugs [5,23,24]. Urinary activity of metallo-
proteinases 2 and 9 has been also associated with renal impairment in
diabetes [25].
Structural and functional impairment of podocytes, which con-
stitute the outer layer of the renal glomerular filtration barrier, play a
pivotal role in the development of diabetic nephropathy [26]. Podo-
cytes are non-dividing and uniquely insulin-sensitive cells in the glo-
merulus of the kidney, in which insulin signaling is not only oriented to
the stimulation of glucose uptake, but also promotes cytoskeletal re-
arrangements, regulating albumin permeability [27]. In the present
study, we demonstrate the presence of CatC in podocytes and shed light
on its role in podocyte function in a hyperglycemic environment. Using
Zucker rats (Crl: ZUC-Leprfa/fa), which are a popular model of insulin
resistance and metabolic syndrome, we also show that the quantity and
activity of CatC in urine can serve as a marker of renal damage.
2. Materials and methods
2.1. Human podocyte cell line
Conditionally immortalized human podocytes (kind gift from Moin
A Saleem) were cultured as described previously [28]. The cells were
cultured at 33 °C to proliferate, and then transferred to 37 °C to dif-
ferentiate for 10–16 days. The expression of podocyte markers (nephrin,
podocin, podocalyxin) was checked, and mycoplasma tests (Myco-
Sensor PCR Assay Kit, Agilent) were performed regularly to ensure cell
line purity.
2.2. Primary rat podocyte culture
Female Wistar rats weighing ~120 g were used to isolate glomeruli
and set up the primary podocyte culture. All of the steps and protocol
were described previously [29]. Cell phenotype was verified by im-
munofluorescence using nephrin and synaptopodin antibodies. All ex-
periments involving animals were approved by the Local Bioethics
Committee (no. 10/2015) and performed in accordance with directive
2010/63/EU.
2.3. Experimental animals and metabolic studies
Obese (n=6) and lean (n=6) male Zucker rats were obtained
from Charles River, Jackson Laboratory (USA). Animals were main-
tained on a 12-h light and dark cycle with free access to standard pellet
diet and tap water. Experiments were performed on 12-week-old rats
kept in separate metabolic cages for 48 h with free access to a regular
pellet diet and drinking water. The rats were allowed to acclimatize
during the first 24 h, and then during the next 24 h urine was collected
and urinary albumin, creatinine, nephrin, and cystatin C excretion
measured using the Rat ALB (Albumin) ELISA Kit (E-EL-R0362,
Elabscience), Creatinine Urinary Detection Kit (EIACUN, Invitrogen),
Rat NPHN (Nephrin) ELISA Kit (ER1196, FineTest), and Rat Cys-C
(Cystatin C) ELISA kit (ER0891, FineTest). Fasting glucose was mea-
sured in whole blood samples using a glucose oxidase method (Accu-
Chek Performa, Roche Diagnostics GmbH). All procedures were ap-
proved by Local Bioethics Committee (no. 10/2015) and applied in
accordance with directive 2010/63/EU.
2.4. Isolation of rat glomeruli for physiological studies
Zucker rat kidneys were removed and placed in ice-cold PBS
(pH 7.4) supplemented with 0.49mM MgCl2, 0.9 mM CaCl2, and
5.6 mM glucose. The renal capsule was removed and the cortex minced
with a razor blade, and then pressed through a system of sieves with
decreasing pore diameters (250, 125, and 75 μm). The whole procedure
was performed on ice and was completed in< 1 h.
2.5. Glomerular permeability to albumin in vitro
The volume response of glomerular capillaries to an oncotic gra-
dient generated by defined concentrations of albumin was analyzed as
described previously [30]. Briefly, the glomeruli were affixed to 0.1%
poly-L-lysine-coated plates and incubated in PBS containing 5% bovine
serum albumin (BSA) with 0.49mM MgCl2, 0.9mM CaCl2, and 5.6 mM
glucose for 15min at 37 °C. The buffer was replaced with fresh buffer
containing 1% BSA to produce an oncotic gradient across the glo-
merular capillary wall (5% BSA in the lumen vs. 1% BSA in the bathing
medium). Control glomeruli were treated with equivalent volumes of
medium containing 5% BSA (no oncotic gradient). The glomerular
volume changes were recorded by videomicroscopy (Olympus IX51)
before and after an oncopressive medium change. Glomerular volume
(V) was calculated from the surface area (A) of the glomerulus using the
following formula using CellSens Dimension software (Olympus):
V= [4/3A A/ ]/106. Volume changes (ΔV) were calculated as
ΔV= (Vfinal− Vinitial)/Vinitial based on the direct relationship between
the increase in ΔV and oncotic gradient applied across the capillary
wall. This principle was used to calculate the reflection coefficient of
albumin (σalb), defined as the ratio of the ΔV for the experimental
glomeruli to the ΔV of control glomeruli in response to identical oncotic
gradients, where σalb= ΔVexperimental/ΔVcontrol. The reflection coeffi-
cient of albumin (convectional Palb) was used to calculate the glo-
merular capillary permeability to albumin (1− σalb), which describes
the movement of albumin consequent to water flow. At least three
glomeruli from obese (n=6) and lean (n=6) Zucker rats were studied
in each experiment.
2.6. Real-time PCR
Total cellular RNA from cultured podocytes was isolated using the
RNeasy Mini Kit (Qiagen) including an on-column DNAse treatment
step (RNase-Free DNase Set, Qiagen). The quantity and purity of RNA
were determined by NanoDrop® (Thermo Scientific). After the reverse
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transcription of isolated RNA, the levels of specified mRNA transcripts
were analyzed by real-time PCR performed in a LightCycler 480
(Roche) using gene-specific intron-spanning primers and fluorescent
hydrolysis probes. The results were quantified by the ∆∆Ct method with
β-actin as an internal control. The amplified products were separated in
a 2.5% agarose gel and imaged by the GelDoc-It Imaging System (UVP,
Cambridge, UK). Primers and probes are characterized in Table 1.
2.7. Western blotting
Podocyte cell lysates were prepared as described previously [29].
Equal amounts of total protein (25 μg per well) were subjected to SDS-
PAGE and then immunoblotted on PDVF membranes. Urinary samples
were centrifuged (20min, 18,000×g, 4 °C), mixed with SDS running
buffer, heated 5min at 95 °C, and run on a 10% gel at volumes nor-
malized to 24 h urine volumes for each tested rat. Densitometric
quantification of the bands was performed with ImageJ software. The
primary antibodies used are described in Table 2.
2.8. Immunofluorescent staining
Podocytes were cultured on glass coverslips coated with type I
collagen. Differentiated cells were fixed in 4% paraformaldehyde,
permeabilized in 0.1% Triton-X 100, and blocked with 3% BSA in PBS.
Next, podocytes were incubated for 2 h with primary antibodies diluted
in 3% BSA. Blocking solution was used instead of primary antibodies as
non-specific staining controls. After extensive washing with PBS and
incubation with secondary fluorescent antibodies, the coverslips were
mounted to slides using Fluoromount Aqueous Mounting Medium
(Sigma-Aldrich). The specimens were imaged using a confocal laser
scanning microscope (Leica SP8X).
2.9. Determination of cathepsin C activity
2.9.1. Sample preparation
Immortalized human podocytes were cultured on 10-cm Petri dishes
at 33 °C to ~80% confluency and then differentiated at 37 °C for
12–14 days. Primary rat podocytes were grown in collagen I-coated T75
flasks at 37 °C for 12–14 days (1.2× 106 cells/flask). A day before the
experiment, cell culture medium was replaced with 4ml EX-Cell Serum
Free Medium (Sigma) in both cell types. The next day, supernatants
were collected and cells lysed in 300 μl of lysis buffer (20mM Tris,
140mM NaCl, 2 mM EDTA, 10% glycerol, 0.001% NP-40, 2mM DTT,
pH 8.0). Protein concentration was assessed in all samples. Twenty-four
hour urine samples were collected from Zucker rats in metabolic cages
as described above.
2.9.2. Measurement of cathepsin C activity
To measure the active form of human CatC, a fluorescent substrate
was used [16]. In the activity assay, the substrate Thi-Ala(Mca)-Ser-Gly-
Tyr(3-NO2)-NH2 (7.5 μM) was incubated at 37 °C with sample diluted in
25mM MES, 50mM NaCl, 2 mM DTT (pH 6). As a specific activity
control, the sample was pre-incubated for 15min with 5 μM of Thi-Phe-
CN, a selective CatC inhibitor [31], at 37 °C in the buffer mentioned
above. The following sample amounts were used: 1.5 μl of cell lysate,
80 μl of cell supernatant, 80 μl of urine. The change in fluorescence
intensity was observed for 90min (λext= 320 nm and λem= 450 nm).
All measurements were performed in triplicate and recorded on a
CLARIOStar (BMG Labtech Germany).
2.10. Albumin permeability of the podocyte monolayer
Transepithelial albumin permeability was evaluated by measuring
FITC-labeled BSA diffusion across a podocyte monolayer as described
previously [32], with minor modifications [29]. Podocytes were seeded
on type IV collagen-coated cell culture inserts (BD Biosciences) placed
in 24-well plates. Podocytes were transfected with control and target
siRNAs and incubated under control or experimental conditions. On the
day of the experiment, the medium was replaced with serum-free
medium (SFM) for 2 h. The medium in the upper compartment was then
replaced with 0.3 ml of fresh SFM, and the medium in the lower com-
partment with 1.5ml of SFM containing 1mg/ml FITC-albumin. After
1 h incubation, 200 μl of solution from the upper chamber was trans-
ferred to a 96-well plate and the FITC-albumin concentration de-
termined based on the absorbance at 490 nm in a plate spectro-
photometer (ELx808, BioTek, USA).
2.11. siRNA transfection
One day before transfection, the podocyte culture medium was re-
placed with antibiotic-free RPMI 1640 supplemented with 10% FBS. On
the day of the experiment, podocytes were incubated for 7 h with CatC
siRNA (80 nM) or scrambled siRNA (80 nM) reconstituted in Opti-MEM
Table 1
Primers and probes used in real-time PCR experiments.






















Primary antibodies used in experiments.
Antibody Clonality Dilution Source
Cathepsin C monoclonal 1:400 Santa Cruz sc-74,590
Nephrin polyclonal 1:1000 Sigma Aldrich PRS2265
Actin monoclonal 1:10000 Sigma Aldrich A3853
GLUT4 polyclonal 1:500 Sigma Aldrich SAB4300667
Cofilin polyclonal 1:400 Sigma Aldrich SAB4500148
p-Cofilin (pSer3) polyclonal 1:3000 Sigma Aldrich SAB4504370
Table 3





unpaired t-test; Mann Whitney test
Glomerular permeability to albumin unpaired t-test
ELISA Mann Whitney test
CatC activity assays paired t-test, one-way ANOVA
Densitometry
ECAR
Mann Whitney test, paired t-test,
unpaired t-test
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(Gibco) containing Transfection Reagent (Santa Cruz Biotechnology).
Equal volumes of RPMI 1640 supplemented with 2-fold higher FBS and
antibiotic concentrations were added for the next 24 h. Gene silencing
was monitored at the protein level by Western blotting.
2.12. Measurement of the extracellular acidification rate (ECAR)
Podocytes were cultured on 8-well culture microplates (Agilent)
coated with Rat Tail Collagen-I Solution (Sigma). On the day of the
experiment, the growth medium was replaced with assay medium
(minimal DMEM supplemented with 2mM L-glutamine) and the cells
Fig. 1. Cathepsin C expression and activity is elevated in urine from obese Zucker rats. (A) Expression of both pro-cathepsin C and its catalytic form was increased in
urine from obese rats (***p < .001 vs. lean, Mann-Whitney test, n=11–16). (B) Representative blot showing the increased quantity of CatC in urine from obese rats
(numbers 1–4 indicate different animals involved in the experiment). The volume of urine samples run in a gel was adjusted to constitute 0.07% of the volume of 24-h
urine collection. (C) Cathepsin C activity was significantly upregulated in obese rats (**p < .01, n=6, Mann-Whitney test). (D) Increased permeability to albumin
was observed in glomeruli isolated from obese rats (**p < .01, n=6, Mann-Whitney test). (E) Urine albumin was elevated in obese rats (*p < .05, n= 6, Mann-
Whitney test). (F) Obese rats had higher urine nephrin levels (*p < .05, n= 6, Mann-Whitney test). (G) Cystatin C is markedly augmented in the urine of obese rats
(**p < .01, n=5, Mann-Whitney test). (H) Creatinine levels in the urine of obese Zucker rats were lower than in their lean counterparts (*p < .05, n= 6, Mann-
Whitney test). A.U., arbitrary units.
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allowed to stabilize at 37 °C for 1 h. The ECAR values were determined
by the Seahorse XFp analyzer (Agilent) before (basic state) and after the
injection of 10mM D-glucose, 1 μM oligomycin, or 50mM 2-deoxy-D-
glucose. The glycolytic flux parameters were obtained from the slopes
of the ECAR values in real-time analyses. Baseline and post-exposure
rates were measured three times every 3min (total time ~80min). The
results were normalized to the protein concentrations determined for
each cell culture plate well using the Bradford method.
2.13. F-actin network
Alexa Fluor™ 647 Phalloidin (ThermoFisher Scientific) was used to
visualize the F-actin network in podocytes cultured on collagen I-coated
coverslips. Fluorescence intensity profiles (from basal membrane to
nucleus) were generated using NIS-Elements General Analysis 3 soft-
ware (Nicon). To normalize the fluorescent profiles from different cells,
the fluorescence intensity of the X-axis at a distance of 1 μm was ex-
pressed as the percentage of the mean value of the fluorescence in-
tensity for the total X-axis and the cell membrane positioned at point 0.
2.14. Statistical analysis
All statistical analyses were performed in GraphPad Prism 8. The
Shapiro–Wilk test was used to determine whether parametric or non-
parametric tests should be implemented. The results are presented as
mean ± SEM. A p-value ≤.05 was considered significant. Statistical
tests used in each experiment are shown in Table 3.
3. Results
3.1. Cathepsin C expression and activity are augmented in the urine of
diabetic Zucker rats
Zucker rats are a popular model of insulin resistance and metabolic
syndrome. The obese (ZO) rats used in experiments (12 weeks old) were
slightly hyperglycemic (Supplemental Table 1), but almost all of them
exhibited considerable polyuria compared to their lean counterparts
(ZL). In proteomic studies, we found that CatC is present in rat urine
and its quantity significantly elevated in urine from ZO rats (both
proCatC and catalytic forms increased by ~65%; Fig. 1A, B). Further-
more, urine CatC activity was higher in ZO rats than ZL littermates
(mean 962 ± 201 A.U. vs. 276 ± 76 A.U., respectively; Fig. 1C). In-
creased albumin permeability was observed in glomeruli isolated from
ZO rats (0.58 ± 0.07 vs. 0.2 ± 0.07 in ZL; Fig. 1D). ZO rats also
showed other signs of renal injury, such as increased urine albumin
(1.293 ± 0.6 vs. 0.488 ± 0.1; Fig. 1E), nephrin (4.1 ± 0.8 vs.
2.25 ± 0.3; Fig. 8F), and cystatin C (7.16 ± 0.7 vs. 1.9 ± 0.3;
Fig. 1G), and decreased levels of urine creatinine (902 ± 51 vs.
1159 ± 82; Fig. 1H).
3.2. Identification of CatC expression in podocytes
We detected CatC expression in both immortalized human podo-
cytes and primary rat podocytes (Fig. 2). Real-time PCR with specific
primers designed to span an intron and fluorescent hydrolysis probes
resulted in an evident band corresponding to the expected product size
(Fig. 2A). In the protein analyses we used mouse monoclonal antibody
for better specificity and detected bands corresponding to the zymogen
form of CatC (proCatC) and the heavy chain of the catalytically active
Fig. 2. Cathepsin C expression in immortalized human podocytes and primary rat podocytes. (A) Real-time PCR products visualized on a 2.5% agarose gel and
corresponding to the amplified fragments of human and rat CatC mRNA isolated from podocytes. (B) CatC protein expression in human and rat podocytes (in
replicates), 25 μg of total protein per lane. (C) Confocal images of CatC and podocyte marker nephrin in human and rat podocytes. Primary antibodies were the same
as in the Western blot studies diluted 1:20, fluorescently labeled secondary antibodies were diluted 1:200. Scale bar= 40 μm. (D) Schematic representation of CatC
maturation and its subunits.
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CatC heterotrimer (Fig. 2B). The same antibody was used to detect CatC
in PFA-fixed podocytes in immunofluorescent studies (Fig. 2C). A
schematic of CatC maturation and subunits is presented in Fig. 2D.
3.3. CatC mRNA expression and activity are upregulated in high glucose-
cultured podocytes
Cathepsins are emerging as important players in the pathogenesis of
diabetic nephropathy; therefore, we analyzed the effects of high glucose
concentration (HG; 30mM, 5 days) on CatC mRNA expression and ac-
tivity. CatC mRNA levels were increased 29% in human podocytes and
80% in primary rat podocytes under HG conditions (Fig. 3A, B). In
addition, CatC activity was elevated 13% and 19% in cell lysates of
human and rat podocytes, respectively (Fig. 3C, D). Analyses of CatC
activity demonstrated that, in podocytes, CatC is not only expressed
intracellularly, but is also secreted outside the cells. We found that CatC
activity is significantly higher in cell supernatants obtained from cells
cultured in HG conditions, with the values increased 25% and 29% in
human and rat cell culture, respectively (Fig. 3C, D).
3.4. HG and PMA stimulate CatC activity and increase albumin
permeability in the primary rat podocyte monolayer
PMA is a known activator of the protein kinase C (PKC) family [33],
and PKC has been shown to activate cathepsins B, K, and L [34].
Therefore, we examined whether PMA (100 nM, 24 h) (Sigma P1585)
stimulates CatC expression and its activity in primary rat podocytes.
PMA increased CatC expression by 18% and significantly stimulated
CatC activity in lysates (by 48%) and supernatants (by 98%) from
primary rat podocytes (Fig. 4A-C). CatC expression and activity were
also markedly upregulated in the HG milieu; CatC expression was in-
creased 49%, whereas CatC activity under HG conditions constituted
118% and 130% of the control in lysates and supernatants, respectively
(Fig. 4A-C). Interestingly, we did not observe a stronger effect of
combined PMA and HG on CatC expression and activity. Furthermore,
both PMA and HG significantly augmented albumin permeability in the
podocyte monolayer (by 96% after PMA stimulation and by 120%
under HG conditions), but there was no additive effect of these factors
(Fig. 4D). Cell viability in HG milieu and after PMA treatment was not
considerably altered (Supplemental Fig. 4).
3.5. Increased podocyte albumin permeability induced by HG and PMA can
be reversed by CatC knockdown
To investigate the potential involvement of CatC in podocyte per-
meability to albumin, we transfected primary rat podocytes with CatC
siRNA and cultured cells in standard medium±PMA (100 nM, 24 h) or
HG medium (30mM, 5 days). CatC downregulation in all systems was
confirmed by Western blot (Fig. 5A). We observed that CatC knock-
down partially restored the expression levels of podocyte marker ne-
phrin in cells cultured in HG and after PMA stimulation (Fig. 5B). In
addition, CatC depletion reversed the negative effects of both PMA and
HG on albumin permeability in podocytes, which was reduced by 19%
(SG+PMA siRNA CatC vs. SG+PMA scrambled siRNA, p < .05) and
by 32% (HG siRNA CatC vs. HG scrambled siRNA, p < .001; Fig. 5C).
3.6. CatC downregulation ameliorates nephrin, cofilin, and GLUT4 levels in
podocytes treated with PMA and HG
Among a variety of different molecular mechanisms of podocyte
Fig. 3. Cathepsin C is upregulated in the hyperglycemic environment. (A) CatC mRNA levels in immortalized human podocytes cultured in standard glucose medium
(SG; 10mM) and high glucose medium (HG; 30mM, 5 days) (*p= .055, n=5–6, unpaired t-test). (B) CatC mRNA levels in primary rat podocytes cultured in SG and
HG conditions (**p < .01, n=6–9, Mann-Whitney test). (C) HG increases intracellular and secreted CatC activity in human podocytes (*p < .05, **p < .01,
n=12, paired t-test). (D) HG stimulates intracellular and secreted CatC activity in primary rat podocytes (***p < .001, n= 12, paired t-test).
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injury in HG, rearrangement of the cytoskeleton underlies the increased
permeability to albumin in the hyperglycemic milieu. Moreover, ab-
normal cytoskeletal changes, such as disrupted cofilin-actin interplay,
promote the development of insulin resistance [35]. Immuno-
fluorescent staining and confocal imaging showed altered expression of
cofilin, an actin-binding protein, and insulin-dependent glucose trans-
porter 4 (GLUT4) after PMA treatment and under HG conditions
(Fig. 6A). Despite observing the cofilin signal in the cell bodies and
membranes of both control and PMA-treated podocytes, the number of
cofilin puncta was markedly reduced in PMA-stimulated cells (Fig. 6A).
In contrast, both PMA and HG exposure reduced the GLUT4 signal,
especially in the podocyte foot processes and cell membranes (Fig. 6A).
Next, we examined whether downregulation of CatC prevents ne-
gative changes exerted by PMA and HG on the expression of GLUT4,
cofilin, and the inactive phosphorylated form of cofilin (p-cofilin). In
podocytes transfected with CatC siRNA, the expression of GLUT4 and
cofilin was ameliorated in PMA and HG-treated podocytes (Fig. 6B-D).
The effect of PMA and HG on the levels of p-cofilin was abolished in
podocytes with CatC knockdown (Fig. 6E).
3.7. HG and PMA induce cytoskeletal rearrangement in podocytes
To confirm our previous results showing that HG and PMA stimu-
lation trigger cytoskeletal rearrangement in podocytes, we analyzed the
F-actin distribution patterns across cells stained with phalloidin. HG
and PMA markedly altered intracellular F-actin localization, which was
especially concentrated in bundles at the cell membranes (Fig. 7A, B).
Moreover, HG and PMA promoted constriction and shrinking of podo-
cyte foot processes (Fig. 7A).
3.8. Glycolytic flux is increased in primary rat podocytes exposed to PMA
Energy metabolism in podocyte foot processes is supported mostly
by glycolysis, as mitochondria are physically larger than the lumen of
the smallest processes [36]. PMA-induced rearrangement of the cytos-
keleton largely alters the morphology of podocytes, especially affecting
foot processes. Therefore, we investigated the potential action of PMA
and HG on glycolytic flux in primary rat podocytes using real-time re-
cording of ECARs (Fig. 8). Effects of PMA were observed in podocytes
cultured in standard glucose (11.1mM) or high glucose (30mM; 5 days)
before the ECAR analysis. PMA significantly increased glycolysis (56%
vs. SG; 74% vs. HG; Fig. 8B), glycolytic capacity (73% vs. SG; 95% vs.
HG; Fig. 8C), and glycolytic reserve (76% vs. SG; 106% vs. HG; Fig. 8D)
in podocytes, but it did not affect non-glycolytic acidification levels
(Fig. 8E).
4. Discussion
The retraction and effacement of podocyte foot processes underlie
the disturbance of podocyte function, which plays a central role in the
development of proteinuria in diabetic nephropathy. Recently, a
number of podocyte proteases that govern the glomerular response to
different metabolic states were revealed [4]. Some members of the
cathepsin family (cathepsin A, C, D), neprilysin, and neutrophil elastase
were also found in the urine exosomes in large-scale proteomic analyses
[37,38]. CatC belongs to the cysteine exopeptidases and predominantly
localizes in lysosomes/endosomes inside the cells, or is secreted into the
extracellular milieu [39]. Some loss-of-function mutations in the CatC
gene have been linked to the development of prepubertal periodontosis,
Fig. 4. PMA and HG effects on cathepsin C in primary rat podocytes and their permeability to albumin. (A) Western blot analyses of CatC expression after PMA
stimulation (100 nM, 24 h) and in HG (5 days) (*p < .05, **p < .01, n=4–6, paired t-test). (B) Confocal imaging of cathepsin C localization in podocytes cultured
in HG or treated with PMA. Scale bar= 50 μm. (C) Cathepsin C activity in podocyte lysates and supernatants after cell exposure to PMA and HG (*p < .05,
***p < .001, n=6–12, one-way ANOVA). (D) PMA and HG effects on FITC-labeled albumin permeability in the podocyte monolayer (**p < .01, ***p < .001,
n= 6–8, unpaired t-test). PMA, phorbol 12-myristate 13-acetate; SG, 11.1 mM D-glucose; HG, 30mM D-glucose.
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Papillon-Lefèvre syndrome, and aggressive periodontosis [40,41]. Up-
regulated CatC activity underlies inflammatory responses in lung dis-
eases, sepsis, and Sendai virus infection [39,42,43]. However, the
functional role of CatC in hyperglycemia-associated podocyte injury
and its possible involvement in the development of diabetic nephro-
pathy have not been investigated thus far.
In this study, we showed that CatC is expressed in podocytes and
secreted into the extracellular space. Interestingly, we observed dif-
ferent intracellular colocalization of CatC and nephrin in human and rat
podocytes. In human cells, most mutual spots were in the cytoplasm,
whereas in rat cells CatC/nephrin dots overlapped mainly within foot
processes and cell membranes, which may be explained by primary
podocytes preserving a well-developed web of long and branched foot
processes in culture. In contrast, immortalized human podocytes dif-
ferentiate in vitro and ultimately their morphology is more simple.
As renal damage occurs in diabetes at least in part via alteration of
the activity of proteolytic enzymes, we analyzed the levels of CatC
expression and activity in podocytes cultured in hyperglycemic
medium. The duration of podocyte exposure to HG was set according to
our previous reports, in which we showed that, after 5 days in HG-
culture, the stimulating effect of insulin on glucose uptake in podocytes
is abolished [44,45]. The development of insulin resistance is strongly
dependent on the cytoskeletal reorganization and altered function of
GLUT1 and GLUT4 [46]. We observed that both PMA (non-specific CatC
activator) and HG induce F-actin rearrangements in cultured podocytes,
which may lead to morphological changes and disturbances in cell
function. We confirmed that elevated CatC expression in podocytes
correlates with increased albumin permeability in vitro. Moreover,
CatC quantity and activity were significantly higher in urine from ZO
rats, along with increased urinary levels of nephrin and albumin. Im-
portantly, CatC depletion markedly ameliorated nephrin and GLUT4
expression in podocytes cultured in the HG milieu, which may improve
insulin sensitivity in podocytes [47].
Cysteine peptidases are emerging mediators in many signaling
pathways in podocytes, and the effects of their enzymatic activity often
involve cytoskeletal rearrangements. Recently, cathepsin L was re-
ported to be overexpressed in several proteinuric kidney diseases, along
with increased levels of dynamin, which regulates the actin network
and nephrin turnover [48]. Another cysteine peptidase, calpain, is an
essential interaction partner for the TRPC6 channel for regulating po-
docyte motility and adhesion to GBM [3]. Interestingly, we observed
significant remodeling of the F-actin network after podocyte stimula-
tion with PMA, a PKC-activating phorbol ester, which also indirectly
activates CatC. It seems plausible that the effect of PMA on the podocyte
cytoskeleton at least partially depends on cofilin inactivation, which is
consistent with several other reports demonstrating altered architecture
and the migration of podocytes when cofilin is downregulated [49,50].
In addition, in our recent paper we proposed a molecular mechanism
for insulin-dependent translocation of GLUT4 from the cytoplasm to the
cell membrane that involves TRPC6/AMPK//Rac1/PAK/cofilin sig-
naling [27]. Here, we showed that the decreased levels of GLUT4 and
cofilin in podocytes exposed to HG and PMA can be restored by CatC
diminution.
The unique podocyte morphology maintained mainly by the actin
cytoskeleton determines the bioenergetic profile of these cells. Evidence
supports a dominant role of anaerobic glycolysis, predominantly
Fig. 5. Cathepsin C downregulation restores nephrin levels and ameliorates albumin permeability in HG and PMA-treated primary rat podocytes. (A) CatC expression
after control (scrambled) or CatC siRNA transfection in podocytes stimulated with PMA (100 nM, 24 h) or cultured in HG (5 days) (*p < .05, n=4, paired t-test,
**p < .01, n=6, Mann Whitney test). (B) Nephrin expression in podocytes transfected with control or CatC siRNA after HG or PMA exposure (*p < .05, **p < .01,
***p < .001, n=7–8, paired t-test). (C) Podocytes transfected with CatC siRNA or control siRNA were subjected to PMA stimulation or were cultured under HG
conditions. The FITC-labeled albumin permeability was measured in the podocyte monolayer (*p < .05, ***p < .001, n=8, Mann Whitney test). (D)
Representative blots including actin loading control. PMA, phorbol 12-myristate 13-acetate; SG, 11.1mM D-glucose; HG, 30mM D-glucose.
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occurring in the foot processes, over oxidative phosphorylation, which
is restricted to mitochondria found primarily in the perinuclear region
and cell bodies [51]. In other studies and our research, PMA, but not
HG, stimulation has been observed to promote the formation of la-
mellipodia and membrane protrusions in podocytes [52]. Therefore, we
investigated whether this morphological alteration is reflected in the
glycolysis flux in podocytes. All of the glycolytic parameters were up-
regulated after PMA treatment, including basic glycolysis, glycolytic
capacity, and reserve. The effect of PMA was also retained in podocytes
cultured in HG, in which glycolytic flux had a tendency to decline,
suggesting a different mechanism of action for both stimuli in glyco-
lysis.
An abnormal podocyte cytoskeletal rearrangement underlies not
only increased albumin permeability, but also the development of in-
sulin resistance [53,54]. In our in vivo studies, we employed genetically
modified obese Zucker rats, which served as a model of type 2 diabetes,
exhibiting improper glucose metabolism and hyperinsulinemia. We
demonstrated for the first time that both the activity and expression of
CatC is significantly upregulated in the urine of obese Zucker rats. Of
course, this does not mean that urinary CatC levels reflect just the po-
docyte pool of the enzyme, but this finding indicates that CatC may play
a role in podocyte function under diabetic conditions, and that it can
serve as a marker for renal injury in diabetes. It would be of interest to
determine whether higher levels of CatC appear in urine before albu-
minuria in order to detect renal injury earlier in the course of diabetes
and implement appropriate pharmacological treatment to slow the
progression of diabetic nephropathy. Additionally, the increased Cy-
statin C level, together with the decreased urinary creatinine level in
Zucker obese rats may reflect not only the podocytes damage, but can
be also related to the alteration of other renal structures, e.g. proximal
tubules.
In conclusion, the results propose a novel mechanism of podocyte
injury in diabetes and provide deeper insight into the role of CatC in
podocyte biology. It seems plausible that a better understanding of the
pivotal molecular mechanisms contributing to podocyte functioning
would provide promising therapeutic targets, which may be pharma-
cologically or genetically modulated in order to prevent the develop-
ment of diabetic nephropathy and establish more effective treatments
for diabetes.
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